Fig 1: CD39 activity shows substrate inhibition. (a) CD39 activity was measured in the presence of varying concentrations of substrate, either ATP or ADP. Data are mean ± s.e.m. (n = 3) and are fitted to a substrate inhibition model as described in the “Methods”. (b) Shows the same data for the lowest substrate concentrations, for clarity.
Fig 2: Combined free energy landscape (FEL) of CD39-2-MeS-ADP and most stable conformations. (a) The combined FEL plot of CD39-2-MeS-ADP complexes. (b) The conformations of the basins in the FEL. The Ca2+ ion is shown as a green sphere while the residues that form H-bonds are shown in bold.
Fig 3: CD39 activity with 2-MeS-ATP or 2-MeS-ADP as substrate. (a) CD39 activity was measured in the presence of varying concentrations of substrate, either 2-MeS-ATP or 2-MeS-ADP. Data are mean ± s.e.m. (n = 3) and are fitted to a substrate inhibition model as described in the “Methods”. (b) Shows the same data for the lowest substrate concentrations, for clarity.
Fig 4: Combined free energy landscape (FEL) of CD39-UDP and most stable conformations. (a) The combined FEL plot of CD39-UDP complexes. (b) The conformations of the basins in the FEL. The Ca2+ ion is shown as a green sphere while the residues that form H-bonds are shown in bold.
Fig 5: CD39 activity shows substrate inhibition with UTP and GTP. (a, c) CD39 activity was measured in the presence of varying concentrations of substrate, either UTP or UDP (a), or GTP or GDP (c). Data are mean ± s.e.m. (n = 3) and are fitted to a substrate inhibition model as described in the “Methods”. (b, d) show the same data for the lowest substrate concentrations, for clarity. (e, f) CD39 activity was measured in the presence of varying concentrations of UMP (e) or GMP (f), with 24 μM substrate (UTP in e, GTP in f). Data are normalised to CD39 activity in the absence of UMP or GMP (control = 100%). n = 3.
Supplier Page from R&D Systems, a Bio-Techne Brand for Recombinant Human CD39/ENTPD1 Protein, CF